{"protocolSection":{"identificationModule":{"nctId":"NCT00129246","orgStudyIdInfo":{"id":"NIAAAOMA15632-B"},"secondaryIdInfos":[{"id":"P50AA015632","type":"NIH","link":"https://reporter.nih.gov/quickSearch/P50AA015632"},{"id":"NIH Grant 9 P50-AA15632"}],"organization":{"fullName":"Yale University","class":"OTHER"},"briefTitle":"Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain","officialTitle":"Naltrexone & Bupropion to Stop Smoking With Less Weight Gain"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-12"},"completionDateStruct":{"date":"2005-12","type":"ACTUAL"},"studyFirstSubmitDate":"2005-08-09","studyFirstSubmitQcDate":"2005-08-09","studyFirstPostDateStruct":{"date":"2005-08-11","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-01-02","resultsFirstSubmitQcDate":"2013-01-02","resultsFirstPostDateStruct":{"date":"2013-02-05","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-11-18","lastUpdatePostDateStruct":{"date":"2020-12-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Yale University","class":"OTHER"},"collaborators":[{"name":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","class":"NIH"}]},"descriptionModule":{"briefSummary":"This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.","detailedDescription":"This is an open label smoking cessation clinical trial of 25 mg naltrexone with 300 mg bupropion sustained-release (SR) in six male and fourteen female participants. This pilot study is being conducted to determine:\n\n* effect size estimates for smoking cessation and post-cessation weight gain, which will be used to compute the sample size needed for a large-scale clinical trial; and\n* compliance with a combination of 25 mg naltrexone and 300 mg bupropion SR. In addition to examining the sample in this study, the investigators plan to compare this sample to a sample of matched controls."},"conditionsModule":{"conditions":["Smoking","Nicotine Dependence"],"keywords":["Tobacco","Smoking","Weight","Weight perception","Naltrexone","Bupropion"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bupropion only","type":"ACTIVE_COMPARATOR","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).","interventionNames":["Drug: Bupropion"]},{"label":"Naltrexone +Bupropion","type":"EXPERIMENTAL","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).","interventionNames":["Drug: Naltrexone","Drug: Bupropion"]}],"interventions":[{"type":"DRUG","name":"Naltrexone","description":"Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.","armGroupLabels":["Naltrexone +Bupropion"]},{"type":"DRUG","name":"Bupropion","description":"Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.","armGroupLabels":["Bupropion only","Naltrexone +Bupropion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Smoking Cessation","description":"Smoking cessation is defined as the number of patients that displayed continuous 6-week abstinence from the quit date.","timeFrame":"Week 6"},{"measure":"Point Prevalence Abstinence","description":"Point prevalence abstinence is defined as the number of patients reporting point prevalence abstinence over the last 7 days.","timeFrame":"Week 6"},{"measure":"Weight Gain","description":"Weight gain for for the entire sample in pounds at 6 weeks.","timeFrame":"Week 6"}],"secondaryOutcomes":[{"measure":"Weight Gain Abstinent Participants","description":"Weight gain (in pounds) for the patients that were continuously abstinent at 6 weeks.","timeFrame":"Week 6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages 18 and older\n* Willingness and ability to give written consent\n* Smoking at least 10 cigarettes per day for at least 1 year\n* Baseline expired carbon-monoxide level of at least 10 ppm\n* Weigh at least 100 lbs.\n* English-speaking\n* One person per household\n* At least 1 prior quit attempt\n* Concern about gaining weight. This will be assessed using a questionnaire that will provide a rating system to determine qualified participants.\n\nExclusion Criteria:\n\n* Pregnant or nursing women or women attempting to conceive\n* Serious current neurologic, psychiatric or medical illness, including unstable cardiac, hepatic, or renal disease and diabetes and hypertension\n* Current alcohol dependence\n* Current use of opiates, and/or a urine toxicology screen positive for opiates\n* Chronic pain conditions necessitating opioid treatment (naltrexone, an opioid antagonist will make these medications ineffective)\n* Evidence of significant hepatocellular injury as evidenced by AST or ALT \\>3 x normal or elevated bilirubin\n* History of cirrhosis\n* Body mass index (BMI) greater than 35\n* History of anorexia nervosa or bulimia\n* Current major depression\n* Currently taking Toprol-XL (or metoprolol succinate)\n* History of seizure disorder or serious brain injury\n* Current use of smokeless tobacco, pipes, cigars, nicotine gum, nicotine patch, nicotine inhaler, nicotine lozenge, nicotine nasal spray, or bupropion\n* Previous hypersensitivity to bupropion\n* Patients requiring concomitant therapy with any psychotropic drug\n* Participation in the Framing Messages for Smoking Cessation With Bupropion study (HIC#: 10880)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Benjamin Toll, Ph.D.","affiliation":"Yale University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Yale University School of Medicine Substance Abuse Treatment Unit","city":"New Haven","state":"Connecticut","zip":"06511","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}}]},"referencesModule":{"references":[{"pmid":"17587504","type":"RESULT","citation":"Toll BA, Leary V, Wu R, Salovey P, Meandzija B, O'Malley SS. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain. Addict Behav. 2008 Jan;33(1):173-9. doi: 10.1016/j.addbeh.2007.05.012. Epub 2007 Jun 2."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"FG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"BG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"40"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42.3","spread":"12.3"},{"groupId":"BG001","value":"43.0","spread":"11.2"},{"groupId":"BG002","value":"42.7","spread":"11.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"28"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Smoking Cessation","description":"Smoking cessation is defined as the number of patients that displayed continuous 6-week abstinence from the quit date.","populationDescription":"Per protocol analysis","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 6","groups":[{"id":"OG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"OG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"PRIMARY","title":"Point Prevalence Abstinence","description":"Point prevalence abstinence is defined as the number of patients reporting point prevalence abstinence over the last 7 days.","populationDescription":"Per protocol analysis","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Week 6","groups":[{"id":"OG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"OG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"}]}]}]},{"type":"SECONDARY","title":"Weight Gain Abstinent Participants","description":"Weight gain (in pounds) for the patients that were continuously abstinent at 6 weeks.","populationDescription":"Per protocol analysis","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"lbs","timeFrame":"Week 6","groups":[{"id":"OG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"OG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.17","spread":"2.04"},{"groupId":"OG001","value":"1.67","spread":"3.17"}]}]}]},{"type":"PRIMARY","title":"Weight Gain","description":"Weight gain for for the entire sample in pounds at 6 weeks.","populationDescription":"Per protocol analysis","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"lbs","timeFrame":"Week 6","groups":[{"id":"OG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."},{"id":"OG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"2.90"},{"groupId":"OG001","value":"0.28","spread":"3.88"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Bupropion Only","description":"The placebo comparator was a group of matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen in a similar 7-week study investigation compared to naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day).\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.","seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":8,"otherNumAtRisk":20},{"id":"EG001","title":"Naltrexone +Bupropion","description":"The active comparator in this 7-week open label study investigation was naltrexone hydrochloride (25 mg/day) in combination with bupropion hydrochloride SR (300 mg/day) compared to matched controls who received an identical psychosocial intervention and bupropion SR treatment regimen (bupropion only).\n\nNaltrexone : Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.\n\nBupropion : Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.","seriousNumAffected":0,"seriousNumAtRisk":20,"otherNumAffected":9,"otherNumAtRisk":20}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":20}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Headache","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Dizziness","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Fatigue","organSystem":"General disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Nervousness/anxiety","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":20}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":20}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":20}]},{"term":"Dry mouth","organSystem":"General disorders","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":20},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":20}]},{"term":"Irritability","organSystem":"Psychiatric disorders","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":20}]},{"term":"Ringing in ears","organSystem":"Ear and labyrinth disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":20}]},{"term":"Sweating","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":20}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"pointOfContact":{"title":"Benjamin A. Toll, PhD","organization":"Associate Professor of Psychiatry and Program Director, Smoking Cessation Service at Smilow Cancer Hospital at Yale-New Haven","email":"benjamin.toll@yale.edu","phone":"(203) 974 5767"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D012907","term":"Smoking"},{"id":"D014029","term":"Tobacco Use Disorder"},{"id":"D001835","term":"Body Weight"}],"ancestors":[{"id":"D001519","term":"Behavior"},{"id":"D019966","term":"Substance-Related Disorders"},{"id":"D064419","term":"Chemically-Induced Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D009271","term":"Naltrexone"},{"id":"D016642","term":"Bupropion"}],"ancestors":[{"id":"D009270","term":"Naloxone"},{"id":"D009019","term":"Morphinans"},{"id":"D053610","term":"Opiate Alkaloids"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D006572","term":"Heterocyclic Compounds, Bridged-Ring"},{"id":"D006576","term":"Heterocyclic Compounds, 4 or More Rings"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D010616","term":"Phenanthrenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D011427","term":"Propiophenones"},{"id":"D007659","term":"Ketones"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}